Daniel (Dan) Swerdlow is currently in the role of Senior Director and Physician Scientist at GSK where he’s the clinical development lead for phase 1 antibody and oligonucleotide assets. Dan trained at UCL where he completed his degree in medicine and PhD in genetic epidemiology. Since then, he’s held various positions including Drug Discovery Physician at BenevolentAI and as Senior Director at Silence Therapeutics.